Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Pharmaceutical firm Eli Lilly made a $10m equity investment in UK-based immunometabolic drug developer Sitryx on Tuesday as part of a licensing and research collaboration deal involving a $50m upfront payment and up to $820m in milestone payments. Sitryx closed a $30m series A round in late 2018 that was co-led by SV Health Investors…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.